Autobio Diagnostics Co., Ltd.
Research Autobio Diagnostics Co., Ltd. (603658.SS) on Bullrun: market cap CNY 22.31B, P/E 21.1, dividend yield 3.4%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker603658.SS
- ExchangeSS
- CountryChina
- SectorHealthcare
- IndustryMedical Devices
- CurrencyCNY
- Market capCNY 22.31B
- P/E21.1
- Dividend yield3.4%
- Financial periodQ2 2026
- RevenueCNY 1.07B
- Net incomeCNY 260.68M
- Free cash flow-CNY 24.38M
- Gross margin67.8%
Valuation Snapshot
latest market cap is CNY 22.31B; P/E is 21.1; dividend yield is 3.4%.
Peer valuation comparison
Latest P/E is 21.11x versus a Healthcare sector median of 21.8x (3.2% below).
Latest dividend yield is 3.35% versus a Healthcare sector median of 2.4% (39.6% above).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 22.31B | 21.1 | 3.4% | 1.31 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 1.31 CNY, yield 3.4%.
About Autobio Diagnostics Co., Ltd.
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities. Its immunoassay products consist of AutoLumo S900 and AutoLumo A1860 that provides user experience for small and medium size labs;
ETFs that hold Autobio Diagnostics Co., Ltd.
US-listed ETFs
Autobio Diagnostics Co., Ltd. is held by 13 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Schwab Emerging Markets Equity ETF (SCHE) | <0.01% | 0.06% |
| Vanguard International High Dividend Yield Index Fund ETF Shares (VYMI) | <0.01% | 0.07% |
| Dimensional Emerging Core Equity Market ETF (DFAE) | <0.01% | 0.29% |
| Dimensional Emerging Markets Core Equity 2 ETF (DFEM) | <0.01% | 0.39% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Autobio Diagnostics Co., Ltd.'s market cap?
Autobio Diagnostics Co., Ltd.'s market capitalization is CNY 22.31B.
What is Autobio Diagnostics Co., Ltd.'s P/E ratio?
Autobio Diagnostics Co., Ltd.'s price-to-earnings (P/E) ratio is 21.1.
Does Autobio Diagnostics Co., Ltd. pay a dividend?
Autobio Diagnostics Co., Ltd. has a dividend yield of 3.4%.
What does Autobio Diagnostics Co., Ltd. do?
Autobio Diagnostics Co., Ltd. engages in the research and development, production, marketing, sale, and service of clinical diagnostic products in China and internationally. The company offers immunoassay, biochemistry, and microbiology products; reagents and instruments; and technical and support, and training services, as well as engages in biology research and development activities.